Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
about
Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancyGuidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)A multimodal approach to the management of neuroendocrine tumour liver metastasesAssessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumoursThe norepinephrine transporter and pheochromocytoma.A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.Targeted radionuclide therapy.Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor.Liver metastases from neuroendocrine tumors.Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas.Modeling combined radiopharmaceutical therapy: a linear optimization framework.Norepinephrine Transporter as a Target for Imaging and Therapy.Carcinoid-syndrome: recent advances, current status and controversies.
P2860
Q33247993-E68E0968-A50B-414D-AAD4-FF75CFDE134EQ35760798-4A6C0975-49B5-4E7F-B330-7939DC7ECE9EQ35810562-7E28B6E0-EF87-4F85-85D8-198732481D29Q36510103-48531E4C-0E76-455C-BA19-D492CE0FD211Q36652797-BD2AE9E2-32A1-45FD-A2A4-3807C55D96CAQ37002905-0BFC058E-50E6-4000-B9F7-EA3D3A4474C5Q37148148-BFC908FE-C2E3-4A01-8287-093E8742C184Q37454406-6B6DC0C9-80D7-4CAA-9ABA-6E6CE33EFDFFQ37864159-273885A4-7B43-4867-90C6-BEADD7D2D6B0Q37990403-2B05D3DA-A631-4F9A-A091-1404F7AE7650Q38262113-55103FD8-CFC8-4136-8D86-A31A8DC75332Q38283682-834704B9-5595-4A20-81C2-59DB286EF1C0Q38542762-3167E44D-FA87-4AA3-8890-326013D26C90Q38956091-1AFEFEC7-EDA2-4C3E-9324-45F0D1A8AF62Q40315003-BCCD8458-2D4E-47CB-82EC-68CA4B78B8A0Q43121154-C76D0F8E-CB26-4474-B597-D63F2FEF4DD5Q46149964-6063A7F1-B29C-49B6-8EB4-27390AC56F98Q47867820-4A2DFA80-70F6-400D-9238-8269DBC093CEQ50094023-FF720237-A932-4686-8F52-C4D8F5EE247B
P2860
Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Iodine-131 metaiodobenzylguani ...... inoid. Results in 98 patients.
@ast
Iodine-131 metaiodobenzylguani ...... inoid. Results in 98 patients.
@en
type
label
Iodine-131 metaiodobenzylguani ...... inoid. Results in 98 patients.
@ast
Iodine-131 metaiodobenzylguani ...... inoid. Results in 98 patients.
@en
prefLabel
Iodine-131 metaiodobenzylguani ...... inoid. Results in 98 patients.
@ast
Iodine-131 metaiodobenzylguani ...... inoid. Results in 98 patients.
@en
P2093
P356
P1433
P1476
Iodine-131 metaiodobenzylguani ...... inoid. Results in 98 patients.
@en
P2093
Douglas S Tyler
Jerome Feldman
John A Olson
Jon P Gockerman
Joseph Moore
Mark W Onaitis
R Edward Coleman
Shawn D Safford
P304
P356
10.1002/CNCR.20592
P407
P577
2004-11-01T00:00:00Z